Payment overview · 2025
General Payments
$1,197.86
18 reported records · 9 companies
Healthcare provider profile · identity verified
Daniel Haimowitz, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · LEVITTOWN, PA · NPI 1013064377
Verified facts
What the public records show
CMS Open Payments records show Daniel Haimowitz, MD received $1,197.86 in general payments during 2025 across 18 reported records.
PFIZER INC. accounted for 74.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuplazid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 381 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $892.32 | 74.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $121.12 | 10.1% | 6 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $35.69 | 3.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.33 | 2.8% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $32.39 | 2.7% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $22.30 | 1.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.85 | 1.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.14 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.72 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $621.95 | 1 |
| Food and Beverage | $305.54 | 16 |
| Travel and Lodging | $270.37 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $141.97 | 7 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.33 | 2 | 2025 |
Source payment records
|
|||||
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
381 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 611 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 571 | 83 |
| Furosemide | Furosemide | 507 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 452 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 450 | 62 |
| Eliquis | Apixaban | 381 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 336 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 299 | 50 |
| Gabapentin | Gabapentin | 297 | 41 |
| Lisinopril | Lisinopril | 294 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 283 | 49 |
| Losartan Potassium | Losartan Potassium | 274 | 41 |
| Potassium Chloride | Potassium Chloride | 241 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 230 | 29 |
| Sertraline Hcl | Sertraline Hcl | 228 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 218 | 32 |
| Omeprazole | Omeprazole | 218 | 36 |
| Lorazepam | Lorazepam | 215 | 36 |
| Metformin Hcl | Metformin Hcl | 205 | 28 |
| Tramadol Hcl | Tramadol Hcl | 189 | 30 |
| Carvedilol | Carvedilol | 156 | 25 |
| Levetiracetam | Levetiracetam | 153 | 23 |
| Mirtazapine | Mirtazapine | 151 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 24 |
| Donepezil Hcl | Donepezil Hcl | 140 | 20 |
| Simvastatin | Simvastatin | 140 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 120 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 20 |
| Alprazolam | Alprazolam | 109 | 17 |
| Trazodone Hcl | Trazodone Hcl | 108 | 20 |
| Montelukast Sodium | Montelukast Sodium | 106 | 12 |
| Xarelto | Rivaroxaban | 106 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 19 |
| Memantine Hcl | Memantine Hcl | 100 | 14 |
| Famotidine | Famotidine | 99 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 28 |
| Nystatin | Nystatin | 87 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 84 | 11 |
| Buspirone Hcl | Buspirone Hcl | 82 | 15 |
| Baclofen | Baclofen | 81 | 12 |
| Myrbetriq | Mirabegron | 81 | 11 |
| Warfarin Sodium | Warfarin Sodium | 81 | suppressed |
| Pregabalin | Pregabalin | 80 | 11 |
| Risperidone | Risperidone | 74 | 11 |
| Clonazepam | Clonazepam | 72 | suppressed |
| Loperamide | Loperamide Hcl | 72 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | suppressed |
| Ibuprofen | Ibuprofen | 66 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | suppressed |
| Valsartan | Valsartan | 63 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Latanoprost | Latanoprost | 61 | 11 |
| Finasteride | Finasteride | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | suppressed |
| Aripiprazole | Aripiprazole | 56 | suppressed |
| Prednisone | Prednisone | 54 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | 12 |
| Bumetanide | Bumetanide | 52 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Digoxin | Digoxin | 45 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Olanzapine | Olanzapine | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 23 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 20 |
| Naproxen | Naproxen | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Rivastigmine | Rivastigmine | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Cephalexin | Cephalexin | 18 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levetiracetam Er | Levetiracetam | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,197.86 · 18 records | PFIZER INC. | AIRSUPRA, INGREZZA, LOREEV XR, MOUNJARO, NUPLAZID, REXULTI, TERIPARATIDE, Xolair | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error